

STAND. COM. REP. NO.

3075

Honolulu, Hawaii

MAR 22 2018

RE: H.B. No. 2384
H.D. 1

Honorable Ronald D. Kouchi
President of the Senate
Twenty-Ninth State Legislature
Regular Session of 2018
State of Hawaii

Sir:

Your Committee on Commerce, Consumer Protection, and Health,
to which was referred H.B. No. 2384, H.D. 1, entitled:

"A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED
SUBSTANCES ACT,"

begs leave to report as follows:

The purpose and intent of this measure is to amend the
Uniform Controlled Substances Act to provide flexibility and clear
guidance for practitioners who prescribe, administer, or dispense
certain controlled substances for patients undergoing medically
managed withdrawal or detoxification treatment.


Your Committee received testimony in support of this measure
from the Department of Health, Department of Public Safety, Hawaii
Substance Abuse Coalition, Drug Policy Forum of Hawaii, and
Coalition for a Drug-Free Hawaii.

Your Committee finds that this measure will bring Hawaii law
into conformity with federal law, and permit registered medical
practitioners to prescribe drugs including buprenorphine and
naloxone for "medically managed withdrawal", also known as
"detoxification treatment" and "maintenance treatment". Your
Committee finds that this measure will not limit the use of these
drugs for medical purposes but will assist in the enforcement of
drug laws and prevention of drug abuse and diversion in the State.



As affirmed by the record of votes of the members of your Committee on Commerce, Consumer Protection, and Health that is attached to this report, your Committee is in accord with the intent and purpose of H.B. No. 2384, H.D. 1, and recommends that it pass Second Reading and be referred to your Committee on Judiciary.

Respectfully submitted on
behalf of the members of the
Committee on Commerce, Consumer
Protection, and Health,



ROSALYN H. BAKER, Chair



